MAPT and dementia: CSF Aβ42 levels are usually reduced years before clinical symptoms of dementia appear (Buchhave et al., 2012), and CSF Aβ42 is therefore considered a candidate biomarker for early AD, alone or in combination with other CSF biomarkers such as total tau (t-tau) representing axonal degeneration, or phosphorylated tau representing tau hyperphosphorylation (Hansson et al., 2006; Tapiola et al., 2009).